Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell Carcinoma

Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes

“…21 Of note, 4 patients in this series were managed with robotic surgery, helping supplement the literature regarding the feasibility of this approach. 22 Patients with a single site of locoregional recurrence had significantly improved secondary recurrence-free survival, as well as higher cancer-specific survival that did not meet traditional levels of statistical significance, compared to patients with multiple sites of locoregional recurrence. This is consistent with the findings of the analysis of the ASSURE trial, where patients with type IV recurrences (> 1 site of locoregional recurrence) were associated with worse survival outcomes vs other recurrence pattern types.…”

“…Out of 3038 total patients, 1895 had clinically localized RCC, with 30 patients (1.6%) having isolated LR/RR. Median time to recurrence was 26.5 months (IQR: [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]. Of 26 patients treated with local therapy, 14 (53.8%) recurred over a median follow-up time of 29.5 months (IQR: .…”

“…Primary recurrence pathology, grade, and histologic subtype when available (20/30 patients) were consistent with initial RCC pathology, grade, and histologic subtype. The median time to primary LR and/or RR following initial nephrectomy for RCC was 26.5 months (IQR: [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35].…”

Metastasectomy in renal cell carcinoma: where are we now?

“…In a recent and presumably the largest case series to date, authors included 12 patients who underwent robotic-assisted minimally invasive excision of ipsilateral RCC recurrence. Study results showed that this approach is feasible, well tolerated, and oncologically sound [18]. Despite the small numbers, these results present minimally invasive surgery as a viable alternative to open surgical resection of limited local recurrence and potentially for other sites of metastasis.…”

“…In RCC, brain metastasis has a reported incidence of 2–17% [18]. To date, multiple studies have reported that complete resection of metachronous brain metastasis, especially in patients with a solitary lesion, may be curative in selected patients.…”